Summary: This ADC product is comprised of an anti-CD22 monoclonal antibody conjugated via a DIBO linker to a doxorubicin. The doxorubicin is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, doxorubicin binds to DNA, causes DNA damage. http://www.creative-biolabs.com/adc/target-cd22-10.htm